



February 4, 2015

MediWound to Ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in Recognition of Burn Awareness Week

YAVNE, Israel, Feb. 4, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Gal Cohen, MediWound's Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in recognition of the American Burn Association's Burn Awareness Week taking place from February 1-7, 2015.

"We are delighted to close the NASDAQ stock market in recognition of Burn Awareness Week, as MediWound has devoted its efforts to advancing burn care for more than a decade," noted Mr. Cohen. "The NASDAQ has provided MediWound with the platform to raise capital to support our efforts to bring an innovative, minimally-invasive modality to burn care. Our lead product, NexoBrid®, enables burn specialists to use a four-hour, non-surgical, bedside application to swiftly debride burns while still protecting the patients' unharmed tissue. NexoBrid is approved and marketed throughout Europe. We are committed to advancing our efforts to make NexoBrid available to U.S. and pediatric burn specialists through our clinical phase 3 trials and to extending NexoBrid's reach to additional emerging international markets through agreements with local distribution partners."

Mr. Cohen and the MediWound management team will ring the closing bell on February 5, 2015 from 3:45 p.m. to 4:00 p.m. ET. A live webcast will be available at: <https://new.livestream.com/nasdaq/live>.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

Contacts:

Sharon Malka

CFO

MediWound

ir@mediwound.co.il

Anne Marie Fields

Senior Vice President

LHA

212-838-3777

afields@lhai.com



Source: MediWound

News Provided by Acquire Media